p53 mutation, deprivation and poor prognosis in primary breast cancer
about
Zeranol down-regulates p53 expression in primary cultured human breast cancer epithelial cells through epigenetic modificationThe RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancersAdiposity is associated with p53 gene mutations in breast cancerSocioeconomic inequalities in mortality from conditions amenable to medical interventions: do they reflect inequalities in access or quality of health care?Household income is associated with the p53 mutation frequency in human breast tumorsRace and the prognostic influence of p53 in women with breast cancer.p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scaleAnalytical Validation of AmpliChip p53 Research Test for Archival Human Ovarian FFPE Sections.High frequency of complex TP53 mutations in CNS metastases from breast cancer.Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancerImmunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcomIntegration of molecular pathology, epidemiology and social science for global precision medicine.Socioeconomic status, p53 abnormalities, and colorectal cancerMultiparameter DNA content analysis identifies distinct groups in primary breast cancer.Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer.Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma.Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.The importance of nonpharmacogenetic factors in endocrine therapy.Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes.Clinical significance of PICT1 in patients of hepatocellular carcinoma with wild-type TP53.Analysis of Tumor Biology to Advance Cancer Health Disparity Research.
P2860
Q24617837-939FF7CE-1711-4C4C-AAB7-9C0D124E8A2DQ33728889-88523C2B-93C4-4642-B88C-4D22A7FF0E66Q33908211-B281D23E-1627-47CF-A841-452B01CC35E7Q34266394-999CC722-C542-45E7-8737-7B975988955CQ34613059-8D5CA695-FFB3-4D3A-A615-2D50C715A576Q34796332-1757385C-C0D0-4407-91E6-8275C7424EB3Q35029530-074AD09F-F62B-4E07-B52B-53D689C5A88CQ35144499-E29D935F-6217-4590-A799-D4C0D53E1111Q35678565-F54CB780-8D6D-4331-94DF-D836D62E0F4AQ35682017-20225AB6-36EF-4280-88C7-D64058270677Q36188758-F64368A2-D47C-4DA2-8E33-F6D9BED03C15Q36245509-21DD568D-35B9-44E7-B02F-87FF91EC711EQ36463854-E924BED9-45FA-406B-8BF7-3715D17F6630Q36582570-FBFDDC3A-6D0F-4C05-94AF-A6ECD10A334DQ36663655-93CC4180-8164-4AC3-B053-FF3E24C7B9F6Q37309651-29CC5989-5CAE-4AD4-9F0D-0BA377F79FE8Q37367403-2813D748-2107-4D75-B5BA-B8A174859B85Q37564385-5D43F57E-3379-4F4A-AAC1-20C550314DFDQ37605645-BE72BA9E-9CC3-4B48-8731-3C7E6166327DQ38003706-A2A29BF6-42D2-4E2C-ADD8-69DF8F1ADF55Q38709284-06D378AB-B363-45AE-8FD4-589B25476B02Q38965092-0E6FEFD3-29E6-4C2C-8EE1-1719C6D27AB6Q39009607-56CEBD75-8B0F-4C6D-B0C6-081A599C8C9FQ39070644-171FE3A2-16B8-4980-BF15-0DB43BA96059Q40789369-19E42386-15DA-4F39-9C0B-D2AA1DAA642BQ45910989-DF450838-E81F-41CD-BED7-06BDE9A9F425Q46324231-A2181C5B-D726-48ED-8EB9-42EF9C1B4AA3
P2860
p53 mutation, deprivation and poor prognosis in primary breast cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
p53 mutation, deprivation and poor prognosis in primary breast cancer
@ast
p53 mutation, deprivation and poor prognosis in primary breast cancer
@en
type
label
p53 mutation, deprivation and poor prognosis in primary breast cancer
@ast
p53 mutation, deprivation and poor prognosis in primary breast cancer
@en
prefLabel
p53 mutation, deprivation and poor prognosis in primary breast cancer
@ast
p53 mutation, deprivation and poor prognosis in primary breast cancer
@en
P2093
P2860
P50
P356
P1476
p53 mutation, deprivation and poor prognosis in primary breast cancer
@en
P2093
A Ashfield
A M Thompson
L B Jordan
L-J Birse-Stewart-Bell
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605540
P407
P577
2010-01-26T00:00:00Z
P5875
P6179
1053176450